Vest Financial LLC Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Vest Financial LLC boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 73.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,728 shares of the medical equipment provider's stock after acquiring an additional 2,003 shares during the period. Vest Financial LLC's holdings in Intuitive Surgical were worth $2,342,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after acquiring an additional 731 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Intuitive Surgical during the 4th quarter worth approximately $6,509,000. Triasima Portfolio Management inc. acquired a new position in Intuitive Surgical during the 4th quarter valued at approximately $266,000. Conning Inc. raised its holdings in shares of Intuitive Surgical by 7.4% in the fourth quarter. Conning Inc. now owns 3,629 shares of the medical equipment provider's stock worth $1,894,000 after buying an additional 249 shares during the last quarter. Finally, TFG Advisers LLC lifted its stake in shares of Intuitive Surgical by 9.0% during the fourth quarter. TFG Advisers LLC now owns 821 shares of the medical equipment provider's stock worth $429,000 after buying an additional 68 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insiders Place Their Bets

In related news, EVP Robert Desantis sold 11,545 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the transaction, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,607,925.28. The trade was a 68.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 215 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $549.06, for a total transaction of $118,047.90. Following the sale, the senior vice president now directly owns 1,768 shares of the company's stock, valued at approximately $970,738.08. This represents a 10.84% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,443 shares of company stock worth $12,692,195. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Down 0.2%

Shares of Intuitive Surgical stock opened at $557.08 on Friday. The firm has a market cap of $199.67 billion, a PE ratio of 86.91, a P/E/G ratio of 5.85 and a beta of 1.67. Intuitive Surgical, Inc. has a twelve month low of $413.52 and a twelve month high of $616.00. The business has a 50-day moving average price of $521.99 and a 200 day moving average price of $539.24.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The business had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same period in the previous year, the business earned $1.50 earnings per share. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. BTIG Research set a $560.00 target price on Intuitive Surgical and gave the company a "buy" rating in a research report on Monday, April 14th. Erste Group Bank raised Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Thursday. Barclays decreased their target price on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Royal Bank of Canada cut their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $596.05.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.